Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded and public sector purchasing by UN and other procurement agenciesNovartis making treatment available on largely not-for-profit basis in areas where malaria is endemic East Hanover, April 24, 2026 – Novartis today announced that the World Health Organization (WHO)...
Samsung, NAND: Xi'an transition slows bit outputView: Chosun Biz suggests that process upgrades at Xi'an (moving from 1289 layer NAND to newer nodes) are weighing on total output (even if the shift to higher layer counts eventually should yield greater bit output).With NAND supply already unsustain
A Closer Look at FY1Q26 (March) ResultsRevenueTotal revenue of $22.39 billion (up 16% y/y) came in just above the Street’s $22.10 billion estimate as deliveries of 358.0k came below the Street’s estimate of 365.6k due to a decrease in vehicle deliveries and lower regulatory credit revenue while see
AAPLWith Cook leaving as CEO this will be a monumental conference call for Apple. Investors will be laser focused on Cook's comments around leaving and breadcrumbs around the much anticipated AI strategy now under Ternus. Back to numbers, Apple will announce its FY2Q26 (March) results on April 30th
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.